Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX

Avoro Capital Advisors LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 72.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,250,000 shares of the biotechnology company’s stock after selling 3,250,000 shares during the period. BioCryst Pharmaceuticals makes up 0.1% of Avoro Capital Advisors LLC’s portfolio, making the stock its 28th biggest holding. Avoro Capital Advisors LLC owned about 0.59% of BioCryst Pharmaceuticals worth $9,488,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership increased its position in shares of BioCryst Pharmaceuticals by 2,103.7% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 4,278,555 shares of the biotechnology company’s stock valued at $38,336,000 after purchasing an additional 4,084,403 shares during the last quarter. Qube Research & Technologies Ltd raised its position in BioCryst Pharmaceuticals by 152.3% in the 2nd quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company’s stock worth $21,266,000 after purchasing an additional 1,432,824 shares during the period. Bank of America Corp DE grew its stake in shares of BioCryst Pharmaceuticals by 97.9% during the second quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company’s stock valued at $25,457,000 after buying an additional 1,405,498 shares during the last quarter. BNP Paribas Financial Markets lifted its position in BioCryst Pharmaceuticals by 1,059.7% in the second quarter. BNP Paribas Financial Markets now owns 1,456,857 shares of the biotechnology company’s stock valued at $13,053,000 after purchasing an additional 1,331,230 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 6.1% in the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock valued at $165,393,000 after purchasing an additional 1,246,633 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Down 1.9%

NASDAQ BCRX opened at $8.22 on Friday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.31. The company has a market capitalization of $2.06 billion, a P/E ratio of 6.85 and a beta of 0.74. The stock’s 50-day moving average price is $7.31 and its 200-day moving average price is $7.41.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The firm had revenue of $163.28 million during the quarter, compared to analysts’ expectations of $151.32 million. During the same period in the prior year, the company posted ($0.13) earnings per share. The company’s revenue for the quarter was up 209.1% compared to the same quarter last year. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 21,773 shares of the business’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.65, for a total value of $166,563.45. Following the sale, the insider owned 398,751 shares in the company, valued at approximately $3,050,445.15. The trade was a 5.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Evercore assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 target price on the stock. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. HC Wainwright lifted their price objective on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Royal Bank Of Canada reduced their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.64.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.